Gregory L. Huson

Array ( [id] => 20511334 [patent_doc_number] => 20260035435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-05 [patent_title] => APPROACHES FOR THE SELECTIVE DEPLETION OF PLA2R-SPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 19/286887 [patent_app_country] => US [patent_app_date] => 2025-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 185 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19286887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19800543 [patent_doc_number] => 20250066468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => LIPOSOME ENCAPSULATED AFFINITY DRUG [patent_app_type] => utility [patent_app_number] => 18/734619 [patent_app_country] => US [patent_app_date] => 2024-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18734619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418536 [patent_doc_number] => 20240294659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases [patent_app_type] => utility [patent_app_number] => 18/645607 [patent_app_country] => US [patent_app_date] => 2024-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18645607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846763 [patent_doc_number] => 20250092114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => NKG2D-FC FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/632737 [patent_app_country] => US [patent_app_date] => 2024-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18632737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19159019 [patent_doc_number] => 20240151726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => DIAGNOSTIC METHODS FOR LIVER DISORDERS [patent_app_type] => utility [patent_app_number] => 18/413155 [patent_app_country] => US [patent_app_date] => 2024-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18413155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034584 [patent_doc_number] => 20240084399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRPALPHA - CD47 INTERACTION [patent_app_type] => utility [patent_app_number] => 18/518353 [patent_app_country] => US [patent_app_date] => 2023-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18518353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018960 [patent_doc_number] => 20240075131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => PD-1 Peptide Inhibitors [patent_app_type] => utility [patent_app_number] => 18/388036 [patent_app_country] => US [patent_app_date] => 2023-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18388036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19004958 [patent_doc_number] => 20240069029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => PD-ECGF AS BIOMARKER OF CANCER [patent_app_type] => utility [patent_app_number] => 18/384508 [patent_app_country] => US [patent_app_date] => 2023-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18384508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096457 [patent_doc_number] => 20240115684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 18/492311 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18492311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003533 [patent_doc_number] => 20240067604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI PD-1/PD-L1 ANTIBODIES FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/492339 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18492339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921345 [patent_doc_number] => 20240024349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => TREATMENTS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) [patent_app_type] => utility [patent_app_number] => 18/374023 [patent_app_country] => US [patent_app_date] => 2023-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6509 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18374023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157754 [patent_doc_number] => 20240150461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => ANTI-CD47 AGENT-BASED OVARIAN CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 18/373655 [patent_app_country] => US [patent_app_date] => 2023-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18373655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318367 [patent_doc_number] => 20240239910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => BI-SPECIFIC ACTIVATORS FOR TUMOR THERAPY [patent_app_type] => utility [patent_app_number] => 18/472418 [patent_app_country] => US [patent_app_date] => 2023-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19049382 [patent_doc_number] => 20240091351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 18/469844 [patent_app_country] => US [patent_app_date] => 2023-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38662 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18469844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19770020 [patent_doc_number] => 20250051446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => Anti-CD28 Humanized Antibodies Formulated for Administration to Humans [patent_app_type] => utility [patent_app_number] => 18/463454 [patent_app_country] => US [patent_app_date] => 2023-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18463454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19049416 [patent_doc_number] => 20240091385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => METHODS OF ASSESSING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATION AND OF IDENTIFYING AND TREATING PATIENTS LIKELY TO BENEFIT FROM GLUCOCORTICOID RECEPTOR MODULATION [patent_app_type] => utility [patent_app_number] => 18/460226 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18460226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034215 [patent_doc_number] => 20240084030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => INTERNALIZING RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS [patent_app_type] => utility [patent_app_number] => 18/359562 [patent_app_country] => US [patent_app_date] => 2023-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18359562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895238 [patent_doc_number] => 20240010723 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => ANTIBODIES TARGETED TO CD147 [patent_app_type] => utility [patent_app_number] => 18/347295 [patent_app_country] => US [patent_app_date] => 2023-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23662 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18347295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19186312 [patent_doc_number] => 20240165225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells [patent_app_type] => utility [patent_app_number] => 18/344653 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23601 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895207 [patent_doc_number] => 20240010692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => RECOMBINANT POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/330740 [patent_app_country] => US [patent_app_date] => 2023-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18330740 [rel_patent_id] =>[rel_patent_doc_number] =>)